Pharmaceutical

BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer

The Opdivo/Yervoy combination demonstrated statistically and clinically significant improvements in the Phase III CheckMate-9DW study.

Jul 20, 2024 - 04:00
BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer
The Opdivo/Yervoy combination demonstrated statistically and clinically significant improvements in the Phase III CheckMate-9DW study.
Read the original article

Tags:

Previous Article

Global study by Hawaiʻi Institute of Marine Biology demonstrates benefit of mari...

Next Article

Tech leader’s $125m boosts Parker Institutes immunotherapy research

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pan Cancer T raises funds through seed extension round

Pan Cancer T raises funds through seed extension round

Jul 14, 2024

Superbugs, antibiotic resistance get renewed scrutiny in Congress

Superbugs, antibiotic resistance get renewed scrutiny i...

Jul 12, 2023

Bayer announces recall of cancer therapy Vitrakvi in US

Bayer announces recall of cancer therapy Vitrakvi in US

Nov 20, 2023